Milestone Pharmaceuticals Inc.
MIST · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 5.00M | 5.00M | -59.64M | -58.39M | -1.35 |
| 2023 FY | 1.00M | 1.00M | -61.10M | -59.69M | -1.39 |
| 2024 FY | — | — | -42.10M | -41.52M | -0.67 |
| 2025 FY | 1.55M | 1.43M | -62.49M | -63.06M | -0.75 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 74.48M | 8.14M | 7.64M | 2.49M | 66.35M |
| 2023 FY | 75.23M | 58.46M | 13.76M | 51.78M | 16.77M |
| 2024 FY | 75.50M | 62.35M | 25.31M | 54.80M | 13.15M |
| 2025 FY | 113.56M | 71.79M | 73.05M | 58.38M | 41.77M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -52.47M | -272.00K | -52.74M | — | -106.51M |
| 2023 FY | -46.42M | -112.00K | -46.54M | — | 6.12M |
| 2024 FY | -28.85M | -33.00K | -28.88M | — | 11.55M |
| 2025 FY | -49.04M | -302.00K | -49.34M | — | 47.73M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 168.10M | 162.96M | — | — | — |
| 2023 FY | 71.74M | 109.75M | — | — | — |
| 2024 FY | 146.82M | 176.30M | — | — | — |
| 2025 FY | 169.44M | 154.77M | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | -12.53M | -12.97M | -0.20 |
| 2025 Q3 | — | -25.00K | -11.90M | -11.92M | -0.12 |
| 2025 Q4 | 1.55M | 1.55M | -17.26M | -17.41M | -0.16 |
| 2026 Q1 | 238.00K | 168.00K | -23.77M | -26.07M | -0.20 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 47.42M | 65.16M | 42.50M | 56.39M | -17.75M |
| 2025 Q3 | 87.75M | 67.25M | 46.69M | 57.21M | 20.50M |
| 2025 Q4 | 113.56M | 71.79M | 73.05M | 58.38M | 41.77M |
| 2026 Q1 | 193.73M | 157.69M | 71.32M | 137.33M | 36.05M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -12.57M | -11.00K | -12.58M | — | -2.59M |
| 2025 Q3 | -9.82M | -1.98K | -9.82M | — | 4.19M |
| 2025 Q4 | -12.78M | -11.00K | -12.79M | — | 26.36M |
| 2026 Q1 | -16.05M | -45.00K | -16.05M | — | -1.73M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 128.78M | 142.67M | — | — | — |
| 2025 Q3 | 132.76M | 143.28M | — | — | — |
| 2025 Q4 | 169.44M | 154.77M | — | — | — |
| 2026 Q1 | 155.04M | 221.05M | — | — | — |